[
  {
    "ts": "2026-01-22T17:00:00+00:00",
    "headline": "4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer",
    "summary": "4D Path’s QPOR™ Platform Selected to Predict Patients’ Responses to TherapyNEWTON, Mass., Jan. 22, 2026 (GLOBE NEWSWIRE) -- 4D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced its participation as an exploratory biomarker collaborator in the Phase II DAD-IO clinical study (NCT04724018) led by Dana-Farber Cancer Institute and supported by Gilead Sciences, Inc. This high-profile study is evalu",
    "url": "https://finance.yahoo.com/news/4d-path-joins-phase-ii-170000474.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "62c5e6a8-47ab-3550-b973-cf5efdcb153b",
      "content": {
        "id": "62c5e6a8-47ab-3550-b973-cf5efdcb153b",
        "contentType": "STORY",
        "title": "4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer",
        "description": "",
        "summary": "4D Path’s QPOR™ Platform Selected to Predict Patients’ Responses to TherapyNEWTON, Mass., Jan. 22, 2026 (GLOBE NEWSWIRE) -- 4D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced its participation as an exploratory biomarker collaborator in the Phase II DAD-IO clinical study (NCT04724018) led by Dana-Farber Cancer Institute and supported by Gilead Sciences, Inc. This high-profile study is evalu",
        "pubDate": "2026-01-22T17:00:00Z",
        "displayTime": "2026-01-22T17:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/b8393220a48b6c52795d63b9711d611d",
          "originalWidth": 1063,
          "originalHeight": 463,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OUjvC5Nx2izVKDOdnM0Oew--~B/aD00NjM7dz0xMDYzO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b8393220a48b6c52795d63b9711d611d.cf.webp",
              "width": 1063,
              "height": 463,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vcT9LdkvvcsCBlt5tvBREA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/b8393220a48b6c52795d63b9711d611d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/4d-path-joins-phase-ii-170000474.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/4d-path-joins-phase-ii-170000474.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]